One drug, one patent?

January 29, 2020, 1:27 AM UTC

This is the web version of Brainstorm Health Daily, Fortune’s daily newsletter on the top health care news. To get it delivered daily to your in-box, sign up here.

Good afternoon, readers.

How should the drug patent system work?

Biopharma executives, unsurprisingly, tend to emphasize the importance of innovation—and regularly argue that strong intellectual property protections are essential to the project of advancing human medicine.

Democratic presidential candidate Michael Bloomberg is taking a different tact, proposing that any new branded pharmaceutical drug should only be able to win one patent.

That would be a massive transformation for the industry if it were to go through. It’s something we need to keep our eyes on.

Read on for the day’s news.

Sy Mukherjee


The scapegoat. We still don't know how this virus (the coronovirus, that is) progresses. It's a complicated procedure. Any vaccine will take months, if not years, to develop. I wish I had more to add, but the reality is: We just don't know what is going on.


How Bank of America's CEO Orchestrated One of the Biggest Comebacks in Baking Historyby Shawn Tully

Why 2020 Is Turning Out to Be a Strong Year for IPOsby Lucinda Shen

Melinda Gates and her $50 Million Donationby Maria Aspan

Sign up for other Fortune newsletters.

Subscribe to Well Adjusted, our newsletter full of simple strategies to work smarter and live better, from the Fortune Well team. Sign up today.

Read More

CEO DailyCFO DailyBroadsheetData SheetTerm Sheet